New site will support demand for high-quality, high-performance healthcare products in China
WILMINGTON, Del. , Oct. 11, 2022 /PRNewswire-PRWeb/ -- DuPont (NYSE:DD) has announced the launch of liveo.dupont.cn, its new DuPont™ Liveo™ Healthcare Solutions regional website serving Greater China . The company actively has expanded its global footprint – with the new website being the latest development – to better serve customers in China and around the world. Insert Injection Molding
The Liveo™ website helps customers find Chinese-language product and application information for the three markets Liveo™ serves:
Biopharma Processing – enabling cost-effective, safe manufacturing of biologics used in innovative drugs and vaccines with a wide range of Liveo™ pharma tubing and overmolded assemblies
Pharmaceutical Solutions – enabling safe, effective new therapeutic drug delivery routes with a unique offering in topical and transdermal solutions, as well as gastrointestinal active pharmaceutical ingredients (APIs)
Medical Devices – enabling safe, convenient, effective diagnostics, monitoring and treatment at the point of care with a broadening range of specialty medical adhesives and elastomers to support the trend for connected devices and wearables.
DuPont also has made other recent investments in the China market. In August, DuPont announced increased production capabilities for its silicone Liveo™ Pharma Tubing by adding manufacturing capacity in eastern China . The manufacturing expansion aims to meet demand for high-purity biopharmaceutical tubing in Greater China .
"DuPont is committed to pursuing investments in healthcare capabilities to meet the needs of our many fast-growing customers, both in China and elsewhere around the world," said DuPont Healthcare & Specialty Lubricants Global Business Director Eugenio Toccalino . "We hope to enable our customers to grow, innovate and save lives as we continue our long-term commitment to the healthcare industry."
The new website can be viewed at liveo.dupont.cn. For Liveo™ product and application information in English, visit liveo.dupont.com.
About DuPont™ Liveo™ Healthcare Solutions DuPont™ Liveo™ is a globally recognized leader in technology for a broad range of innovations in medical devices, biopharmaceutical processing and pharmaceutical solutions. DuPont high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information can be found at liveo.dupont.com.
About DuPont Electronics & Industrial DuPont Electronics & Industrial is a global supplier of new technologies and performance materials serving the semiconductor, circuit board, display, digital and flexographic printing, healthcare, aerospace, industrial, and transportation industries. From advanced technology centers worldwide, teams of talented research scientists and application experts work closely with customers, providing solutions, products and technical service to enable next-generation technologies.
About DuPont DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at http://www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.
On November 2, 2021 , DuPont announced it has entered definitive agreements to acquire Rogers Corporation ("Rogers"), (the "Intended Rogers Acquisition"). On January 25, 2022 , Rogers shareholders approved the transaction. Closing, is expected by the end of the second quarter 2022, subject to regulatory approvals and customary closing conditions.
On February 18, 2022 , DuPont announced that it has entered into definitive agreements to divest a majority of its Mobility & Materials segment, excluding certain Advanced Solutions and Performance Resins businesses, to Celanese Corporation ("Celanese"), (the "M&M Divestiture"). Closing is expected around the end of 2022, subject to regulatory approvals and customary closing conditions.
The Company also announced on February 18, 2022 that its Board of Directors has approved the divestiture of the Delrin® acetal homopolymer (H-POM) business. In addition to the entry into definitive agreements, the Company anticipates that the closing of the sale of Delrin® would be subject to regulatory approvals and other customary closing conditions, (the "Delrin® Business Divestiture" and together with the M&M Divestiture, the "M&M Divestitures").
Cautionary Statement Regarding Forward Looking Statements
This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.
Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties' ability to meet expectations regarding the timing, completion and accounting and tax treatments of the M&M Divestiture to Celanese, including (x) any failure to obtain necessary regulatory approvals, anticipated tax treatment or to satisfy any of the other conditions to the proposed transaction, (y) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies could impact the value, timing or pursuit of the proposed transaction, and (z) risks and costs and pursuit and/or implementation, timing and impacts to business operations of the separation of business lines in scope for the M&M Divestiture to Celanese, (ii) the timing and outcome of the Delrin® Business Divestiture, including entry into definitive agreements, and the risks, costs and ability to realize benefits from the pursuit of the Delrin® Business Divestiture; (iii) ability to achieve anticipated tax treatments in connection with mergers, acquisitions, divestitures and other portfolio changes actions and impact of changes in relevant tax and other laws; (iv) indemnification of certain legacy liabilities; (v) risks and costs related to each of the parties respective performance under and the impact of the arrangement to share future eligible PFAS costs by and between DuPont, Corteva and Chemours; (vi) failure to timely close on anticipated terms (or at all), realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with mergers, acquisitions, divestitures and other portfolio changes including the Intended Rogers Acquisition and the M&M Divestitures; (vii) risks and uncertainties, including increased costs and the ability to obtain raw materials and meet customer needs, related to operational and supply chain impacts or disruptions, which may result from, among other events, the COVID-19 pandemic and actions in response to it, and geo-political and weather related events; (viii) ability to offset increases in cost of inputs, including raw materials, energy and logistics; and (ix) other risks to DuPont's business, operations; each as further discussed in DuPont's most recent annual report and subsequent current and periodic reports filed with the U.S. Securities and Exchange Commission. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.
For further information, contact: Fiona Paul Pinter Global Communications Leader, Healthcare +41 79 5713084 email@example.com
Proposed caption: The recently launched liveo.dupont.cn offers Chinese-language product information and resources to customers in Greater China .
Thin Wall Injection Molding Fiona Paul Pinter , DuPont, +41 79 5713084, firstname.lastname@example.org